Monday, February 6, 2012

GSK 'finding' halts four trials of Anacor antibiotic

GlaxoSmithKline plc suspended enrollment in four trials of an Anacor Pharmaceuticals Inc. antibiotic after a “microbiological finding” in some patients in one of the studies.
The stock of Palo Alto-based Anacor (NASDAQ: ANAC) was down 36 cents, or nearly 5 percent, to $7.06 per share by mid-afternoon, after GSK said Monday that it suspended enrollment around GSK-052 in patients with complicated urinary tract infections.
The finding isn’t related to three other studies of the drug — a Phase IIb trial in complicated intra-abdominal infections and two Phase I trials — but GSK said it voluntarily suspended enrollment in those trials as well.

No comments:

Post a Comment